The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism-Reference-Cited by-同舟云学术

The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism

Published:2009-07 Issue:7 Volume:33 Page:871-875
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Breccia Massimo,Alimena Giuliana

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference36 articles.

1. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukaemia: using guidelines to make rational treatment choices;Kantarjian;J Natl Compr Cnc Netw,2008

2. Evolving molecular therapy for chronic myeloid leukaemia: are we on target?;Copland;Hematology,2005

3. Gastrointestinal stromal tumors: imatinib and beyond;Schnadig;Curr Treat Options Oncol,2006

4. Chronic myeloid leukemia: diagnosis and treatment;Quintas-Cardama;Mayo Clin Proc,2006

5. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia;Druker;N Engl J Med,2006

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review;Frontiers in Pharmacology;2024-02-01

2. The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia;Hemato;2023-07-14

3. Treatment-Free Remission: the New Goal in CML Therapy;Current Hematologic Malignancy Reports;2021-10

4. Metabolic Plasticity Is an Essential Requirement of Acquired Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia;Cancers;2020-11-19

5. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?;Haematologica;2020-10-09